Key Points
- Roger Susi sold 5,000 shares at an average price of $100.38 for $501,900 on March 23, trimming his stake by 0.22% but still holding 2,235,000 shares (~$224.35M).
- iRadimed beat quarterly expectations with $0.54 EPS (vs. $0.49) and $22.69M revenue, and issued Q1 2026 guidance of $0.440–0.480 EPS and FY2026 guidance of $2.060–2.210 EPS.
- The company raised its quarterly dividend to $0.20 (annualized $0.80, ~0.8% yield), while analysts maintain a consensus "Moderate Buy" rating and an average $120 price target.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of iRadimed stock in a transaction dated Tuesday, March 24th. The stock was sold at an average price of $100.28, for a total value of $250,700.00. Following the sale, the chief executive officer directly owned 2,232,500 shares in the company, valued at approximately $223,875,100. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
iRadimed Stock Performance
Shares of IRMD opened at $101.78 on Thursday. iRadimed Corporation has a one year low of $47.48 and a one year high of $107.90. The stock has a 50-day moving average price of $100.54 and a 200 day moving average price of $90.22. The company has a market capitalization of $1.30 billion, a P/E ratio of 58.16 and a beta of 1.12.
iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.
iRadimed Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.20 per share. This is a positive change from iRadimed's previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. iRadimed's payout ratio is currently 45.71%.
Analyst Upgrades and Downgrades
IRMD has been the topic of a number of recent analyst reports. Roth Mkm restated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Weiss Ratings restated a "buy (b-)" rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Lake Street Capital reaffirmed a "buy" rating and set a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $120.00.
Get Our Latest Analysis on IRMD
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Ranger Investment Management L.P. lifted its holdings in iRadimed by 7.4% in the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider's stock worth $12,845,000 after acquiring an additional 14,730 shares during the last quarter. Grandeur Peak Global Advisors LLC grew its holdings in shares of iRadimed by 96.6% during the second quarter. Grandeur Peak Global Advisors LLC now owns 22,165 shares of the medical equipment provider's stock valued at $1,325,000 after purchasing an additional 10,892 shares during the last quarter. Geode Capital Management LLC raised its position in shares of iRadimed by 6.5% during the 2nd quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider's stock worth $15,630,000 after purchasing an additional 15,996 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of iRadimed during the 3rd quarter worth approximately $422,000. Finally, Shaker Investments LLC OH lifted its holdings in shares of iRadimed by 18.9% in the 3rd quarter. Shaker Investments LLC OH now owns 63,199 shares of the medical equipment provider's stock worth $4,497,000 after purchasing an additional 10,056 shares during the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
